Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
CME Education Series
To access individual activity information and to participate, please click the participation button above.
Target Audience
This educational activity is intended for hematology/oncology specialists, pathologists, and oncology care teams.
Description
The management of patients with chronic lymphocytic leukemia and mantle cell lymphoma who are treated with BTK inhibitors comes with intolerance and resistance challenges and therefore there is a continuous unmet need for novel treatments. With that in mind, this Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma was created to provide a broad range of educational activities on ongoing therapeutic developments in a variety of program formats to appeal to your individual learning preferences.
Providers
This activity is developed through a collaboration between The Leukemia & Lymphoma Society and Medscape Oncology.
Supporters
This activity is supported by an independent educational grant from Lilly.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.